002317 众生药业
交易中 12-23 09:36:54
资讯
新帖
简况
众生药业最新公告：控股子公司获得欧洲专利证书
证券之星 · 12-12
众生药业最新公告：控股子公司获得欧洲专利证书
众生药业最新公告：控股子公司获得发明专利证书
证券之星 · 11-29
众生药业最新公告：控股子公司获得发明专利证书
民生证券：给予众生药业买入评级
证券之星 · 11-21
民生证券：给予众生药业买入评级
众生药业(002317.SZ)子公司众生睿创创新药RAY1225注射液减重Ⅱ期临床试验结果达到预期目的
智通财经 · 11-20
众生药业(002317.SZ)子公司众生睿创创新药RAY1225注射液减重Ⅱ期临床试验结果达到预期目的
众生药业(002317.SZ)：RAY1225注射液减重Ⅱ期临床试验获子研究顶线分析数据结果
智通财经 · 11-20
众生药业(002317.SZ)：RAY1225注射液减重Ⅱ期临床试验获子研究顶线分析数据结果
众生药业最新公告：控股子公司RAY1225注射液减重Ⅱ期临床试验获积极结果
证券之星 · 11-20
众生药业最新公告：控股子公司RAY1225注射液减重Ⅱ期临床试验获积极结果
众生药业：控股子公司RAY1225注射液减重Ⅱ期临床试验获积极结果
美港电讯 · 11-20
众生药业：控股子公司RAY1225注射液减重Ⅱ期临床试验获积极结果
众生药业：目前昂拉地韦片正在审评审批阶段，并按照CDE要求正常推进中
证券之星 · 11-18
众生药业：目前昂拉地韦片正在审评审批阶段，并按照CDE要求正常推进中
众生药业：昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组和给药
美港电讯 · 11-17
众生药业：昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组和给药
众生药业(002317.SZ)：昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组
智通财经 · 11-17
众生药业(002317.SZ)：昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组
众生药业最新公告：控股子公司一类创新药昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组
证券之星 · 11-17
众生药业最新公告：控股子公司一类创新药昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组
众生药业（002317）11月14日主力资金净卖出7967.95万元
证券之星 · 11-15
众生药业（002317）11月14日主力资金净卖出7967.95万元
众生药业最新公告：全资子公司获得羧甲司坦口服溶液《药品补充申请批准通知书》
证券之星 · 11-08
众生药业最新公告：全资子公司获得羧甲司坦口服溶液《药品补充申请批准通知书》
众生药业：获羧甲司坦口服溶液药品补充申请批准
美港电讯 · 11-08
众生药业：获羧甲司坦口服溶液药品补充申请批准
华福证券：给予众生药业买入评级
证券之星 · 11-05
华福证券：给予众生药业买入评级
图解众生药业三季报：第三季度单季净利润同比减13.46%
证券之星 · 10-29
图解众生药业三季报：第三季度单季净利润同比减13.46%
众生药业(002317.SZ)发布前三季度业绩，净利润1.49亿元，同比下降46.76%
智通财经 · 10-28
众生药业(002317.SZ)发布前三季度业绩，净利润1.49亿元，同比下降46.76%
众生药业（002317）10月25日主力资金净卖出3449.11万元
证券之星 · 10-28
众生药业（002317）10月25日主力资金净卖出3449.11万元
10月24日众生药业涨5.46%，招商医药健康产业股票基金重仓该股
证券之星 · 10-24
10月24日众生药业涨5.46%，招商医药健康产业股票基金重仓该股
概念掘金 | “长寿药”迎来重大突破，概念股将迎爆发期？
格隆汇 · 10-24
概念掘金 | “长寿药”迎来重大突破，概念股将迎爆发期？
公司概况
公司名称：
广东众生药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-12-11
主营业务：
广东众生药业股份有限公司主营业务是药品研发、生产、销售。公司主要产品有复方血栓通系列产品、众生丸系列产品、头孢克肟分散片、头孢拉定胶囊、硫糖铝口服混悬液。公司为高新技术企业。公司入选“2022中国医药创新企业100强”、“2021年度中国医药工业百强”、“2022年广东省制造业企业500强”。
发行价格：
55.00
{"stockData":{"symbol":"002317","market":"SZ","secType":"STK","nameCN":"众生药业","latestPrice":12.65,"timestamp":1734917814000,"preClose":12.39,"halted":0,"volume":4536600,"delay":0,"floatShares":762000000,"shares":852000000,"eps":0.1557,"marketStatus":"交易中","marketStatusCode":2,"change":0.26,"latestTime":"12-23 09:36:54","open":12.44,"high":12.66,"low":12.35,"amount":56876400,"amplitude":0.025,"askPrice":12.65,"askSize":215,"bidPrice":12.64,"bidSize":9,"shortable":0,"etf":0,"ttmEps":0.1557,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1734924600000},"adr":0,"adjPreClose":12.39,"symbolType":"stock","openAndCloseTimeList":[[1734917400000,1734924600000],[1734930000000,1734937200000]],"highLimit":13.63,"lowLimit":11.15,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":851556477,"pbRate":2.41,"roa":"--","roe":"3.41%","epsLYR":0.32,"committee":-0.351661,"marketValue":10772000000,"floatMarketCap":9634000000,"peRate":81.245987,"changeRate":0.021,"turnoverRate":0.006,"status":0},"requestUrl":"/m/hq/s/002317/wiki","defaultTab":"wiki","newsList":[{"id":"2490487053","title":"众生药业最新公告：控股子公司获得欧洲专利证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2490487053","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490487053?lang=zh_cn&edition=full","pubTime":"2024-12-12 17:30","pubTimestamp":1733995849,"startTime":"0","endTime":"0","summary":"众生药业公告，控股子公司众生睿创收到欧洲专利局颁发的专利证书，发明名称为\"TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME\"，专利号为3293177，专利申请日为2016年4月7日，专利权人为众生睿创，专利权期限为自申请日期二十年。该专利是众生睿创开发的具有治疗特发性肺纤维化和恶性肿瘤双重作用创新药ZSP1603项目的化合物专利，属于该项目的核心专利。ZSP1603项目是国内同靶点第一个获批临床用于治疗IPF的小分子创新药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121200029716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0188","002317"],"gpt_icon":0},{"id":"2487539639","title":"众生药业最新公告：控股子公司获得发明专利证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2487539639","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487539639?lang=zh_cn&edition=full","pubTime":"2024-11-29 18:00","pubTimestamp":1732874431,"startTime":"0","endTime":"0","summary":"众生药业公告，控股子公司众生睿创收到中华人民共和国国家知识产权局颁发的发明专利证书。发明名称为带有修饰结构的多肽及其应用，专利号为ZL202410061582.8，专利申请日为2024年1月16日，专利权人为众生睿创，专利权期限为自申请日起二十年。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112900030254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0077","BK0188"],"gpt_icon":0},{"id":"2485482835","title":"民生证券：给予众生药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2485482835","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485482835?lang=zh_cn&edition=full","pubTime":"2024-11-21 12:00","pubTimestamp":1732161641,"startTime":"0","endTime":"0","summary":"民生证券股份有限公司王班,张梦鸽近期对众生药业进行研究并发布了研究报告《事件点评：减重达标率优于替尔泊肽，高剂量减重效果未来可期》，本报告对众生药业给出买入评级，当前股价为13.6元。PartA较低剂量平行研究部分中，超重/肥胖参与者接受RAY1225注射液3mg、6mg和安慰剂共入组122例，每两周给药一次，连续治疗24周。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级5家；过去90天内机构目标均价为16.94。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112100016576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","161027"],"gpt_icon":0},{"id":"2484903031","title":"众生药业(002317.SZ)子公司众生睿创创新药RAY1225注射液减重Ⅱ期临床试验结果达到预期目的","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903031","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484903031?lang=zh_cn&edition=full","pubTime":"2024-11-20 20:23","pubTimestamp":1732105389,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业 公告，公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新多肽药物RAY1225注射液用于超重/肥胖患者的Ⅱ期临床试验，于近日获得子研究的顶线分析数据。初步结果表明，RAY1225注射液在中国成人超重/肥胖参与者中表现出积极的疗效和良好的安全性，试验结果理想，达到预期目的。RAY1225注射液用于肥胖/超重患者与2型糖尿病患者的两项Ⅱ期临床研究仍在进行中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK0239","BK1583","BK0077","BK1161","06978","BK1576","BK1574","BK1141","BK0188","03347","002317"],"gpt_icon":0},{"id":"2484930631","title":"众生药业(002317.SZ)：RAY1225注射液减重Ⅱ期临床试验获子研究顶线分析数据结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2484930631","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484930631?lang=zh_cn&edition=full","pubTime":"2024-11-20 18:39","pubTimestamp":1732099167,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业 公告，公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新多肽药物RAY1225注射液用于超重/肥胖患者的Ⅱ期临床试验，于近日获得子研究的顶线分析数据。初步结果表明，RAY1225注射液在中国成人超重/肥胖参与者中表现出积极的疗效和良好的安全性，试验结果理想，达到预期目的。公告显示，RAY1225注射液用于肥胖/超重患者与2型糖尿病患者的两项Ⅱ期临床研究仍在进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK1583","03347","BK1576","BK1141","BK0188","002317","BK0239"],"gpt_icon":0},{"id":"2484193794","title":"众生药业最新公告：控股子公司RAY1225注射液减重Ⅱ期临床试验获积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2484193794","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484193794?lang=zh_cn&edition=full","pubTime":"2024-11-20 18:31","pubTimestamp":1732098691,"startTime":"0","endTime":"0","summary":"众生药业公告，控股子公司众生睿创的一类创新多肽药物RAY1225注射液用于超重/肥胖患者的Ⅱ期临床试验获得子研究顶线分析数据。初步结果显示，RAY1225注射液在中国成人超重/肥胖参与者中表现出积极的疗效和良好的安全性，试验结果理想，达到预期目的。RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，属于长效GLP-1类药物，具有GLP-1受体和GIP受体双重激动活性。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000032061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK1583","03347","BK1576","BK1141","BK0188","002317","BK0239"],"gpt_icon":0},{"id":"2484198711","title":"众生药业：控股子公司RAY1225注射液减重Ⅱ期临床试验获积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2484198711","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484198711?lang=zh_cn&edition=full","pubTime":"2024-11-20 18:24","pubTimestamp":1732098243,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1576","BK0188","GLP","002317","BK0077","BK1583","BK4144","BK0239","BK1141","BK4590","03347"],"gpt_icon":0},{"id":"2484645857","title":"众生药业：目前昂拉地韦片正在审评审批阶段，并按照CDE要求正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2484645857","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484645857?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:00","pubTimestamp":1731920426,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)11月18日在投资者关系平台上答复投资者关心的问题。投资者：你好，昂拉地韦新药申请目前进度如何？可否明确回复一下，打消一下市场的担忧疑虑众生药业董秘：您好！目前昂拉地韦片正在审评审批阶段，并按照CDE要求正常推进中。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800021531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0077","BK0239","BK0188"],"gpt_icon":0},{"id":"2484891396","title":"众生药业：昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组和给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2484891396","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484891396?lang=zh_cn&edition=full","pubTime":"2024-11-17 18:41","pubTimestamp":1731840110,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","BK0077","159837","BK1161","BK1141","159992","BK0188","BK1583","BK1576","BK1574","03347","002317","06978"],"gpt_icon":0},{"id":"2484500005","title":"众生药业(002317.SZ)：昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2484500005","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484500005?lang=zh_cn&edition=full","pubTime":"2024-11-17 16:45","pubTimestamp":1731833115,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布公告，公司控股子公司广东众生睿创生物科技有限公司(简称“众生睿创”)自主研发的一类创新药物昂拉地韦颗粒(研发代号：ZSP1273颗粒)治疗2~17岁单纯性甲型流感患者的Ⅱ期临床试验完成首例参与者入组和给药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","BK1141","03347","BK1576","BK0077","BK1583","002317"],"gpt_icon":0},{"id":"2484450012","title":"众生药业最新公告：控股子公司一类创新药昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2484450012","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484450012?lang=zh_cn&edition=full","pubTime":"2024-11-17 16:30","pubTimestamp":1731832214,"startTime":"0","endTime":"0","summary":"众生药业公告，控股子公司众生睿创自主研发的一类创新药物昂拉地韦颗粒（研发代号：ZSP1273颗粒）治疗2~17岁单纯性甲型流感患者的Ⅱ期临床试验完成首例参与者入组和给药。昂拉地韦颗粒的临床前研究结果表明，其对多种甲型流感病毒的抑制能力显著优于奥司他韦和玛巴洛沙韦，且对耐药病毒株和高致病性禽流感病毒株均具有很强的抑制作用。昂拉地韦片的新药上市申请正在审评审批阶段。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111700001110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0077","BK1576","06978","BK0188","03347","002317","159992","BK1141","BK1574","BK1161","BK0239"],"gpt_icon":0},{"id":"2483121369","title":"众生药业（002317）11月14日主力资金净卖出7967.95万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483121369","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483121369?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:21","pubTimestamp":1731633688,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月14日收盘，众生药业报收于13.55元，下跌5.97%，换手率4.98%，成交量37.94万手，成交额5.28亿元。近5日资金流向一览见下表：众生药业融资融券信息显示，融资方面，当日融资买入6034.76万元，融资偿还3957.97万元，融资净买入2076.79万元。众生药业主营业务：药品研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500007781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","002317","BK0188"],"gpt_icon":0},{"id":"2481125382","title":"众生药业最新公告：全资子公司获得羧甲司坦口服溶液《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2481125382","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481125382?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:40","pubTimestamp":1731058859,"startTime":"0","endTime":"0","summary":"众生药业公告，近日收到国家药品监督管理局核准签发的羧甲司坦口服溶液《药品补充申请批准通知书》。药品名称：羧甲司坦口服溶液。羧甲司坦为临床常用黏液调节剂，用于治疗慢性支气管炎、支气管哮喘等疾病引起的痰液黏稠、咳痰困难患者，为国家基本药物目录和医保目录乙类药物。本次获得《药品补充申请批准通知书》标志着此产品视同通过化学仿制药一致性评价，将丰富公司羧甲司坦系列产品管线，提升市场竞争力，对公司今后业绩提升产生积极影响。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800029993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0188","002317"],"gpt_icon":0},{"id":"2481234981","title":"众生药业：获羧甲司坦口服溶液药品补充申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2481234981","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481234981?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:38","pubTimestamp":1731058692,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0077","BK0239","BK0188","002317"],"gpt_icon":0},{"id":"2481512331","title":"华福证券：给予众生药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2481512331","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481512331?lang=zh_cn&edition=full","pubTime":"2024-11-05 12:56","pubTimestamp":1730782577,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司陈铁林近期对众生药业进行研究并发布了研究报告《业绩短期承压，建议关注创新管线进展》，本报告对众生药业给出买入评级，当前股价为13.11元。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为16.94。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500018144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","161027"],"gpt_icon":0},{"id":"2479243086","title":"图解众生药业三季报：第三季度单季净利润同比减13.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479243086","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479243086?lang=zh_cn&edition=full","pubTime":"2024-10-29 01:38","pubTimestamp":1730137110,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业2024年三季报显示，公司主营收入19.08亿元，同比下降7.88%；归母净利润1.49亿元，同比下降46.76%；扣非净利润1.88亿元，同比下降37.21%；其中2024年第三季度，公司单季度主营收入5.44亿元，同比下降7.7%；单季度归母净利润6139.26万元，同比下降13.46%；单季度扣非净利润1471.96万元，同比下降79.17%；负债率21.94%，投资收益2084.08万元，财务费用618.84万元，毛利率56.08%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900001101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317"],"gpt_icon":0},{"id":"2478487083","title":"众生药业(002317.SZ)发布前三季度业绩，净利润1.49亿元，同比下降46.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478487083","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478487083?lang=zh_cn&edition=full","pubTime":"2024-10-28 22:54","pubTimestamp":1730127252,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布2024年三季度报告，前三季度，公司实现营业收入19.08亿元，同比下降7.88%。归属于上市公司股东的净利润1.49亿元，同比下降46.76%。归属于上市公司股东的扣除非经常性损益的净利润1.88亿元，同比下降37.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002317"],"gpt_icon":0},{"id":"2478501111","title":"众生药业（002317）10月25日主力资金净卖出3449.11万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478501111","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478501111?lang=zh_cn&edition=full","pubTime":"2024-10-28 09:20","pubTimestamp":1730078404,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月25日收盘，众生药业报收于13.22元，下跌2.22%，换手率6.44%，成交量49.06万手，成交额6.44亿元。近5日资金流向一览见下表：众生药业融资融券信息显示，融资方面，当日融资买入7084.43万元，融资偿还6854.01万元，融资净买入230.42万元，连续3日净买入累计3350.44万元。众生药业主营业务：药品研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800002151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0188","002317"],"gpt_icon":0},{"id":"2477775735","title":"10月24日众生药业涨5.46%，招商医药健康产业股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2477775735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477775735?lang=zh_cn&edition=full","pubTime":"2024-10-24 16:14","pubTimestamp":1729757646,"startTime":"0","endTime":"0","summary":"证券之星消息，10月24日众生药业涨5.46%，收盘报13.52元，换手率9.65%，成交量73.49万手，成交额9.89亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为招商医药健康产业股票。招商医药健康产业股票的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400025545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0077","BK0188"],"gpt_icon":0},{"id":"2477079547","title":"概念掘金 | “长寿药”迎来重大突破，概念股将迎爆发期？","url":"https://stock-news.laohu8.com/highlight/detail?id=2477079547","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477079547?lang=zh_cn&edition=full","pubTime":"2024-10-24 12:16","pubTimestamp":1729743405,"startTime":"0","endTime":"0","summary":"提高100倍","market":"us","thumbnail":"https://img3.gelonghui.com/61171-1b6b1da9-d8f5-424c-871c-0f5f4f25aea7.jpg?guru_height=854&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/61171-1b6b1da9-d8f5-424c-871c-0f5f4f25aea7.jpg?guru_height=854&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1211129","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4139","002626","BK4505","002728","002317","BK0197","BK0191","300630","BK0201","BK4588","BK0077","BK0174","BK0239","BK0186","RNA","BK0028","300261","BK0188","002562","BK0229","BK4585","BK0226","300267"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-12-11","address":"广东省东莞市石龙镇西湖工业区信息产业园","stockEarnings":[{"period":"1week","weight":-0.044},{"period":"1month","weight":-0.0822},{"period":"3month","weight":0.1377},{"period":"6month","weight":0.0377},{"period":"1year","weight":-0.2103},{"period":"ytd","weight":-0.2172}],"companyName":"广东众生药业股份有限公司","boardCode":"AI0027","perCapita":"8598股","boardName":"医药制造业","registeredCapital":"85155万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":" 广东众生药业股份有限公司主营业务是药品研发、生产、销售。公司主要产品有复方血栓通系列产品、众生丸系列产品、头孢克肟分散片、头孢拉定胶囊、硫糖铝口服混悬液。公司为高新技术企业。公司入选“2022中国医药创新企业100强”、“2021年度中国医药工业百强”、“2022年广东省制造业企业500强”。","serverTime":1734917816899,"listedPrice":55,"stockholders":"88576人(较上一季度减少1.78%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"众生药业,002317,众生药业股票,众生药业股票老虎,众生药业股票老虎国际,众生药业行情,众生药业股票行情,众生药业股价,众生药业股市,众生药业股票价格,众生药业股票交易,众生药业股票购买,众生药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}